{"id":23315,"date":"2008-02-28T15:45:34","date_gmt":"2008-02-28T15:45:34","guid":{"rendered":"https:\/\/corporate.webfactory.ferring.tech\/?p=23315"},"modified":"2021-05-10T19:13:09","modified_gmt":"2021-05-10T18:13:09","slug":"ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/","title":{"rendered":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment"},"content":{"rendered":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h2 style=\"color: #0088ce\">Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<p><em>Plan to launch GnRH blocker in 2009 subject to regulatory approval.<\/em><\/p>\n<h3 style=\"color: #0088ce\">Saint-Prex, Switzerland \u2013 February 28, 2008 \u2013<\/h3>\n<p class=\"p1\">Ferring Pharmaceuticals announced today that it has submitted applications in Europe and the United States for the marketing authorisation of its prostate cancer treatment, degarelix, a new GnRH receptor blocker intended for patients in whom androgen deprivation is warranted.<\/p>\n<p>The applications follow the successful completion of a pivotal phase 3 study, in which degarelix was studied for the speed of the suppression in levels of testosterone, the maintenance of the reduction during the one year study period as well as prostate-specific antigen (PSA) reduction.<\/p>\n<p>&#8220;We believe that the data for degarelix is convincing and demonstrates the benefits that this drug can offer to patients suffering from the most common form of cancer in men,&#8221; said Dr. Pascal Danglas, Ferring&#8217;s Executive Vice President of Clinical and Product Development. &#8220;Subject to approval by regulatory bodies, we plan to start launching globally in 2009.&#8221;<\/p>\n<p>&#8211; Ends &#8211;<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">Notes for editors<\/h3>\n<h4 style=\"color: #0088ce\">About Prostate Cancer<\/h4>\n<p>Prostate cancer is the most common form of cancer in men, and the second leading cause of cancer death. In the US 218,890 new cases were estimated for 2007, with a mortality of 27,050. In 2005 127,490 new cases were diagnosed in the 5 biggest European countries and 18,310 in Japan.<\/p>\n<h3 style=\"color: #0088ce\">About Ferring Pharmaceuticals<\/h3>\n<p>Ferring is a Swiss-based, research driven, speciality biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology.\u00a0 In recent years Ferring has expanded beyond its traditional European base and now has offices in over 40 countries.\u00a0To learn more about Ferring or our products please visit <a href=\"https:\/\/www.ferring.com\/\">www.ferring.com<\/a>.<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_row element_name=&#8221;Row&#8221; wrap_type=&#8221;content-width&#8221; parallax_image_height=&#8221;content-height&#8221; parallax_image_movement=&#8221;fixed&#8221; parallax_image_speed=&#8221;0.5&#8243; bg_video_loop=&#8221;yes&#8221; parallax_video_height=&#8221;window-height&#8221; parallax_video_overlay=&#8221;none&#8221; row_overlay_opacity=&#8221;0&#8243; row_col_pos=&#8221;default&#8221; minimize_row=&#8221;no&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_button button_text=&#8221;READ MORE PRESS RELEASES&#8221; button_size=&#8221;standard&#8221; button_colour=&#8221;accent&#8221; button_type=&#8221;standard&#8221; rounded=&#8221;no&#8221; button_dropshadow=&#8221;no&#8221; button_link=&#8221;\/media\/press-releases\/&#8221; button_target=&#8221;_self&#8221; align=&#8221;center&#8221; animation=&#8221;none&#8221; animation_delay=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [\/spb_row]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Plan to launch GnRH blocker in 2009 subject to regulatory approval. Saint-Prex, Switzerland \u2013 February 28, 2008 \u2013 Ferring Pharmaceuticals announced today that it has submitted [&hellip;]<\/p>\n","protected":false},"author":2410,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[253],"tags":[],"class_list":["post-23315","post","type-post","status-publish","format-standard","hentry","category-press-release-2008"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Plan to launch GnRH blocker in 2009 subject to regulatory approval. Saint-Prex, Switzerland \u2013 February 28, 2008 \u2013 Ferring Pharmaceuticals announced today that it has submitted [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2008-02-28T15:45:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-10T18:13:09+00:00\" \/>\n<meta name=\"author\" content=\"pulse\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"pulse\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\"},\"author\":{\"name\":\"pulse\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\"},\"headline\":\"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment\",\"datePublished\":\"2008-02-28T15:45:34+00:00\",\"dateModified\":\"2021-05-10T18:13:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\"},\"wordCount\":476,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"articleSection\":[\"PRESS RELEASE 2008\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\",\"url\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\",\"name\":\"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"datePublished\":\"2008-02-28T15:45:34+00:00\",\"dateModified\":\"2021-05-10T18:13:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\",\"name\":\"pulse\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"caption\":\"pulse\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment","og_description":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Plan to launch GnRH blocker in 2009 subject to regulatory approval. Saint-Prex, Switzerland \u2013 February 28, 2008 \u2013 Ferring Pharmaceuticals announced today that it has submitted [&hellip;]","og_url":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2008-02-28T15:45:34+00:00","article_modified_time":"2021-05-10T18:13:09+00:00","author":"pulse","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"pulse","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/"},"author":{"name":"pulse","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d"},"headline":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment","datePublished":"2008-02-28T15:45:34+00:00","dateModified":"2021-05-10T18:13:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/"},"wordCount":476,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"articleSection":["PRESS RELEASE 2008"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/","url":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/","name":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"datePublished":"2008-02-28T15:45:34+00:00","dateModified":"2021-05-10T18:13:09+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-submits-new-drug-application-for-degarelix-a-prostate-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d","name":"pulse","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","caption":"pulse"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/23315"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/2410"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=23315"}],"version-history":[{"count":0,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/23315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=23315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=23315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=23315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}